Difference between revisions of "Team:Michigan/Experiments"

Line 4: Line 4:
 
<div class="column full_size">
 
<div class="column full_size">
  
<h1>Experiments</h1>
+
<h3>Building the Attack/Guard Assay:</h3>
<p>Describe the research, experiments, and protocols you used in your iGEM project. These should be detailed enough for another team to repeat your experiments.</p>
+
<p>SaCas9, gRNA for SaCas9, and gRNA for SpCas9 were synthesized by Integrated DNA Technologies. SaCas9 was synthesized from two linearized fragments, with a Ava restriction site near the 5’ end of one and 3’ end of the other to join them into one fragmentThis complete fragment was flanked by EcoRI and PstI sites in order to be compatible for insertion into the submission vector pSB1C3. Once the SaCas9_C plasmid was confirmed, we double digested the SaCas9_C and the gRNA for SaCas9 with SacI and SgrAI and then ligated the fragments, leaving us with one of our final plasmids needed for experiments, SaCas9_C_gRNA, a plasmid containing a LacI coding region for inducible control, the gRNA able to transcribe and bind with SaCas9 in order to target the complementary sequence on the reporter plasmid, and the SaCas9 coding region.
1Make modifications to the plasmids<br />
+
We obtained the SpCas9 DNA from the Zhang lab at the University of Michigan in a pET083 backbone. In order to move the fragment we needed (containing LacI repressor and SpCas9) into pSB1K3, we used PCR mutagenesis to flank our region of interest with EcoRI and PstI cut sites. Once SpCas9_K was confirmed, we double digested with the gRNA for SpCas9 using sites EcoNI and SgrAI. Then we ligated the resulting fragments, leaving us with our final plasmid needed for experiments, SpCas9_K_gRNA, a plasmid containing a LacI Repressor coding region for inducible control, the gRNA able to transcribe and bind with SpCas9 in order to target the complementary sequence on the reporter plasmid, and the SpCas9 coding region.
a. Use PCR to amplify the plasmids<br />
+
 
b. Point mutagenesis with specific primers to introduce digestion sites (to S.pyCas9 Plasmid)<br />
+
Given more time to conduct experiments, we would induce the necessary point mutations in each Cas9 through the use of One-Pot Mutagenesis (see protocol section). This requires primers be designed to anneal to the specific portion of the the sequence where we want to induce our mutations. These mutations will be specific to each Cas9 used since the nuclease domain will be in a different location within the sequence in each case.  
c. Transform in DH5α and plate to isolate colonies<br />
+
   
i. Check to ensure that our point mutation is correct either by Sanger Sequencing or colony PCR with the mutated primers<br />
+
The reporter plasmid (with CFP) was synthesized by Integrated DNA Technologies to contain the necessary target sequence and PAM sequence needed for recognition of SpCas9 and SaCas9 with their respective gRNAs.
d. Digest at the newly introduced sites to cut out the portion of S.pyCas9 plasmid that we need <br />
+
 
e. Ligate this insert into one of the empty backbones from iGEM<br />
+
All restriction digests were performed using New England Biolabs (NEB) restriction enzymes. Qiagen PCR cleanup kits were then used on each restriction digest product. All ligations were performed with NEB T4 ligase at room temperature overnight, then the ligation products were first transformed into homemade DH5a chemically competent cells (see protocol section), but after a couple failed transformations, we used NEB DH5a chemically competent E. coli cells. These transformations were plated and grown overnight. 5mL liquid cultures were prepared from colonies picked from the plates the next day and themselves grown overnight. All DNA extraction was performed using Qiagen miniprep kits. CFP was measured at 398 nm excitation and 498 nm emission via a plate reader (Infinite 200, Techan Life Sciences). Cell density was measured at A600 via the same  plate reader.
f. Clone the SaCas9 that was order into the other empty backbone from iGEM<br />
+
<br />
2. Make point mutations to the WT-Cas9 plasmids to disable nuclease activity and make them dCas9<br />
+
  a. Use primers introduce these point mutations in each of the plasmids <br />
+
  b. Confirm the mutations by transformation into DH5α to separate colonies and submit to purified sample to Sanger Sequencing<br />
+
3. Transform the testing plasmid into BL21 Competent E. coli and use corresponding selection antibiotic to confirm<br />
+
4. Establish Controls<br />
+
All Controls need to be performed on triple selection plates with triple transformation<br />
+
a. Control 1 - Average Colony count with Testing Plasmid and the other empty plasmids <br />
+
b. Control 2 - Average Colony count with WT-SpyCas9, testing plasmid, and the other empty plasmid<br />
+
c. Control 3 - Average Colony count with WT-SaCas9, testing plasmid, and the other empty plasmid<br />
+
d. Control 4 -  Average Colony count with d-SpyCas9, testing plasmid, and the other empty plasmid<br />
+
e. Control 5 - Average Colony count with d-SaCas9, testing plasmid, and the other empty plasmid<br />
+
5. Perform the final competition assay again with triple transformation<br />
+
  
  

Revision as of 01:46, 18 October 2018

Building the Attack/Guard Assay:

SaCas9, gRNA for SaCas9, and gRNA for SpCas9 were synthesized by Integrated DNA Technologies. SaCas9 was synthesized from two linearized fragments, with a Ava restriction site near the 5’ end of one and 3’ end of the other to join them into one fragment. This complete fragment was flanked by EcoRI and PstI sites in order to be compatible for insertion into the submission vector pSB1C3. Once the SaCas9_C plasmid was confirmed, we double digested the SaCas9_C and the gRNA for SaCas9 with SacI and SgrAI and then ligated the fragments, leaving us with one of our final plasmids needed for experiments, SaCas9_C_gRNA, a plasmid containing a LacI coding region for inducible control, the gRNA able to transcribe and bind with SaCas9 in order to target the complementary sequence on the reporter plasmid, and the SaCas9 coding region. We obtained the SpCas9 DNA from the Zhang lab at the University of Michigan in a pET083 backbone. In order to move the fragment we needed (containing LacI repressor and SpCas9) into pSB1K3, we used PCR mutagenesis to flank our region of interest with EcoRI and PstI cut sites. Once SpCas9_K was confirmed, we double digested with the gRNA for SpCas9 using sites EcoNI and SgrAI. Then we ligated the resulting fragments, leaving us with our final plasmid needed for experiments, SpCas9_K_gRNA, a plasmid containing a LacI Repressor coding region for inducible control, the gRNA able to transcribe and bind with SpCas9 in order to target the complementary sequence on the reporter plasmid, and the SpCas9 coding region. Given more time to conduct experiments, we would induce the necessary point mutations in each Cas9 through the use of One-Pot Mutagenesis (see protocol section). This requires primers be designed to anneal to the specific portion of the the sequence where we want to induce our mutations. These mutations will be specific to each Cas9 used since the nuclease domain will be in a different location within the sequence in each case. The reporter plasmid (with CFP) was synthesized by Integrated DNA Technologies to contain the necessary target sequence and PAM sequence needed for recognition of SpCas9 and SaCas9 with their respective gRNAs. All restriction digests were performed using New England Biolabs (NEB) restriction enzymes. Qiagen PCR cleanup kits were then used on each restriction digest product. All ligations were performed with NEB T4 ligase at room temperature overnight, then the ligation products were first transformed into homemade DH5a chemically competent cells (see protocol section), but after a couple failed transformations, we used NEB DH5a chemically competent E. coli cells. These transformations were plated and grown overnight. 5mL liquid cultures were prepared from colonies picked from the plates the next day and themselves grown overnight. All DNA extraction was performed using Qiagen miniprep kits. CFP was measured at 398 nm excitation and 498 nm emission via a plate reader (Infinite 200, Techan Life Sciences). Cell density was measured at A600 via the same plate reader.

Please remember to put all characterization and measurement data for your parts on the corresponding Registry part pages.

What should this page contain?

  • Protocols
  • Experiments
  • Documentation of the development of your project